Q2 2023
Cambrian Bio
Creating therapeutics that have the potential to treat and prevent some of today’s most debilitating chronic diseases
Each issue covers our major company developments, significant events from the quarter, insightful contributions from our team, updates on our pipeline developments, and team spotlights. With our newsletter, you'll never miss a beat and will always be informed and engaged with all things Cambrian Bio.?
Major Developments
Cambrian's latest pipeline program aims to improve state-of-the-art cell and gene therapies by generating more biologically fit cells, overcoming cell aging, and replicative lifespan limits caused by critically short telomeres.
Nature Biotechnology published, "Defining a longevity biotechnology company," which was led by our team member Nicola Boekstein and featured many other leaders in the space. The review acknowledges the increasing interest and investment in longevity drug development and proposes a framework to positively contribute to the field.
Momentous Occasions
Our CFO/COO?Juliette Han, PhD. attended the FT's US Pharma and Biotech summit where she participated in a panel discussing how investments in technology and innovation will transform clinical trials.
Our CEO James Peyer, PhD. met with longevity leaders to discuss the roadmap towards a healthier decade through concrete identified projects and actions with a big impact.
Get the Inside Scoop: Hear from Our Team
James Peyer, PhD. joined the Biotech 2050 podcast to discuss the driving force behind his interest in aging biology and oncology, how his perspective on aging has changed over the years, and what he hopes is achieved in this field over the next decade.
领英推荐
Juliette Han, PhD. joined?Jarret Banks, MBA., of?IPO Edge on the NYSE floor for a brief conversation about the business side of biotech. She discussed areas of growth, innovation, management challenges, data-driven decision-making, and gave a glimpse of what's on the horizon for us.
Keep Up with Our Pipeline
"Over the next 5 years, we expect results from a rapidly expanding list of human clinical trials as well as work in canines and non-human primates to shed light on the viability of mTOR inhibition as a therapy for aging-related conditions." Joan Mannick?the CEO of our PipeCo?Tornado Therapeutics on her latest review, Targeting the biology of aging with mTOR inhibitors.
?Cambrianite Spotlight
From the blog
Our VP of Global Policy and Strategic Initiatives, Adrienne Hallett introduces our latest blog segment "An Ounce of Longevity" where she will explore the policy implications of healthy longevity medicines. In her first segment, she shares what healthy aging means to her and highlights the implications for families, communities, societies, and economies.?
Our EVP of Drug Discovery, Georg C. Terstappen, shares how his passion drove him to embark on what became a 30-year journey through the biopharmaceutical industry, and why he has chosen to continue his journey with Cambrian. He also highlights the remarkable progress of Isterian, one of our PipeCo’s that he heads, and its promising lead-stage TG2 inhibitor which offers a compelling path forward for IPF.
In the News